#JPM2025
LightNews LightNews
aspenbio.bsky.social
Aspen Biosciences
@aspenbio.bsky.social
The past couple of years have been challenging for biotech companies. At #JPM2025, investors were looking for two things: Phase II results, and a #DigitalTransformation story that showed how #AI, #automation and advanced analytics would be used to advance early stage programs into the clinic.
October 22, 2025 at 4:36 AM Everybody can reply
2 likes
1 2
markfortner.bsky.social
Mark Fortner
@markfortner.bsky.social
When I see headlines like this in the run up to #jpm2025 it makes me wonder if M&A should be seen as a sign of weakness rather than strength in the market. After all if a company is strong enough (well funded enough) to stand on its own feet why would it need M&A to achieve its goals?
Biopharma Heads to JP Morgan Seeking an M&A Spark to Improve Sentiment
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.
www.biospace.com
January 6, 2025 at 4:03 PM Everybody can reply
3 likes
1 3
rasushrestha.bsky.social
Dr Rasu Shrestha
@rasushrestha.bsky.social
✅ LATEST AGENDA for #JPM2025

Here it is folks. Welcome to the 43rd Annual J.P.Morgan Healthcare Conference - alongside CEOs of >500 leading #healthcare companies globally.

I always get 3 months of meetings done in 3 days at #JPM25.

#MedSky #jpmhc25
The 43rd Annual JPMorgan Healthcare Conference will welcome more than 500 leading Healthcare companies from around the world – ranging from Fortune 100 corporations to small-cap and emerging private companies – along with thousands of global investors and thought-leaders representing industry, the markets, academia, government and philanthropy. This past year brought a number of challenges that roiled Healthcare markets and beyond, including an eventful election cycle, global economic uncertainty, persisting geopolitical and trade tensions, difficult debt market conditions, and wars in Ukraine and the Middle East. Also like the last four years, when we marveled at the speed with which our industry took on the pandemic, this year we witnessed incredible advances in the treatment of metabolic, neurodegenerative and autoimmune diseases. The 43rd Annual JPMorgan Healthcare Conference will welcome more than 500 leading Healthcare companies from around the world – ranging from Fortune 100 corporations to small-cap and emerging private companies – along with thousands of global investors and thought-leaders representing industry, the markets, academia, government and philanthropy. This past year brought a number of challenges that roiled Healthcare markets and beyond, including an eventful election cycle, global economic uncertainty, persisting geopolitical and trade tensions, difficult debt market conditions, and wars in Ukraine and the Middle East. Also like the last four years, when we marveled at the speed with which our industry took on the pandemic, this year we witnessed incredible advances in the treatment of metabolic, neurodegenerative and autoimmune diseases. The 43rd Annual JPMorgan Healthcare Conference will welcome more than 500 leading Healthcare companies from around the world – ranging from Fortune 100 corporations to small-cap and emerging private companies – along with thousands of global investors and thought-leaders representing industry, the markets, academia, government and philanthropy. This past year brought a number of challenges that roiled Healthcare markets and beyond, including an eventful election cycle, global economic uncertainty, persisting geopolitical and trade tensions, difficult debt market conditions, and wars in Ukraine and the Middle East. Also like the last four years, when we marveled at the speed with which our industry took on the pandemic, this year we witnessed incredible advances in the treatment of metabolic, neurodegenerative and autoimmune diseases. The 43rd Annual JPMorgan Healthcare Conference will welcome more than 500 leading Healthcare companies from around the world – ranging from Fortune 100 corporations to small-cap and emerging private companies – along with thousands of global investors and thought-leaders representing industry, the markets, academia, government and philanthropy. This past year brought a number of challenges that roiled Healthcare markets and beyond, including an eventful election cycle, global economic uncertainty, persisting geopolitical and trade tensions, difficult debt market conditions, and wars in Ukraine and the Middle East. Also like the last four years, when we marveled at the speed with which our industry took on the pandemic, this year we witnessed incredible advances in the treatment of metabolic, neurodegenerative and autoimmune diseases.
January 12, 2025 at 11:25 AM Everybody can reply
3 likes
3
invernatx.com
Inverna Therapeutics
@invernatx.com
🌟 Inverna is heading to JPM Week in SF! 🌟
Our CEO, Poul Sørensen, will share our vision for disease-modifying therapies for Huntington’s disease, powered by our RNA splicing platform.
📅 Attending too? Let’s connect to discuss partnerships and innovation!

#jpm2025 #biotech #huntington #rnasplicing
🌟 Inverna is heading to San Francisco! 🌟 We’re thrilled to announce that Inverna and our CEO, Poul Sørensen, will be attending the annual JPM Week, one of the most prestigious events in the biotech and healthcare industry. This marks an exciting opportunity for Inverna to share our vision and connect with industry leaders, innovators, and collaborators. As we continue our work in developing disease-modifying therapeutics for Huntington’s disease through our novel RNA splicing modulation platform, we are eager to engage with those who share our passion for groundbreaking science. 📅 If you’re attending the conference and would like to discuss partnerships, innovation, or simply learn more about our journey, we’d love to meet you! Let’s build the future of biotech together.
January 8, 2025 at 8:57 AM Everybody can reply
1 reposts 5 likes
1 1 5
recursionpharma.bsky.social
Recursion
@recursionpharma.bsky.social
Advancing our vision for a virtual cell: In a presentation at #JPM2025, CEO Chris Gibson shared his vision for #TechBio, in which biol & chem datasets & highly predictive ML models, including advanced protein folding, will allow us to build a true virtual cell. ir.recursion.com/static-files...
January 13, 2025 at 6:42 PM Everybody can reply
3 reposts 7 likes
3 7
gwencheni.bsky.social
Gwen Cheni
@gwencheni.bsky.social
Takeaways from JPM Healthcare Conf 2025 #JPM2025 For having survived the past two years of biotech winter and current political uncertainties, the crowd was pretty cautiously optimistic for dealflow to recover. And yes, the word “agentic” AI should have been a drinking game.🧵👇
January 17, 2025 at 2:01 AM Everybody can reply
3 likes
1 3
rasushrestha.bsky.social
Dr Rasu Shrestha
@rasushrestha.bsky.social
🔮 Key prediction for #JPM2025:

With a major patent cliff coming, #JPM25 will play host to some serious deal-making.

Do you agree?

#biopharma #medsky
Between now and 2033, the patents on dozens of brand-name medications will expire, allowing generic drugmakers to begin selling cheaper versions. Drug companies stand to lose more than $400 billion in revenue as patents expire for Keytruda, Eliquis, Jardiance, Opdivo, and other blockbuster therapies. (By comparison, the last major patent cliff that hit the industry, in 2011, jeopardized around $250 billion in drug revenue.)
January 12, 2025 at 1:43 PM Everybody can reply
4 likes
1 4
cogensus.bsky.social
Cogensus
@cogensus.bsky.social
Co-founder Raju Joshi and Chief of Staff Hall Wang are looking forward to attending #JPM2025 next week to highlight Cogensus’ potential to redefine the #AgeTech industry by leveraging #AI in elderly care.

Set up a meeting with our leadership by emailing [email protected] 🧠

#Cogensus
January 9, 2025 at 11:30 PM Everybody can reply
pandemiccenter.bsky.social
Pandemic Center at Brown University’s School of Public Health
@pandemiccenter.bsky.social
Biopharma innovators and investors attending #JPM2025, RSVP now to join NTI|bio on Jan. 16 at 7:30 AM PT for Michelle McMurry-Heath in conversation with experts Emma Wheatley of @cepivaccines.bsky.social, @jennifernuzzo.bsky.social, and @jaimeyassif.bsky.social

Read More here👇
nti.org Nuclear Threat Initiative @nti.org · Jan 7
Biopharma innovators and investors attending #JPM2025, RSVP now to join NTI | bio on Jan. 16 at 7:30 AM PT to explore how the shifting political environment & emerging biological risks could impact business opportunities & building global health security.
January 7, 2025 at 5:15 PM Everybody can reply
1 likes
1
arpa-h.bsky.social
ARPA-H
@arpa-h.bsky.social
If you are at #JPM2025 Healthcare Week, check out the PROSPR presentation today with our Program Manager Andrew Brack at the @R42 Longevity Showcase! lu.ma/0gan7pm5
ARPA-H Dr. Andrew Brack, Program Manager, Resilient Systems is speaking at the R42 Longevity Showcase. Headshot on a dark blue background.
January 13, 2025 at 8:44 PM Everybody can reply
2 likes
2
rasushrestha.bsky.social
Dr Rasu Shrestha
@rasushrestha.bsky.social
😮‍💨 “…it’s a dangerous time to be a child in the United States.”

#medsky #JPM2025
January 13, 2025 at 12:53 PM Everybody can reply
2 reposts 1 quotes 1 likes
2 1
michaelwong.bsky.social
Michael Wong
@michaelwong.bsky.social
Recharged by the inspiring discussions with current and prospective partners at #JPM2025. Our industry undoubtedly has flaws but there are a lot of great people at the helm seeking to make a difference in drug discovery and healthcare.
Now back to the bitter cold week ahead in Boston…
January 20, 2025 at 2:11 PM Everybody can reply
vinguptamd.bsky.social
Dr. Vin Gupta
@vinguptamd.bsky.social
To my extended healthcare community, if you’ll be in SF at #JPM2025, send me a note or DM.

Some great events with the country’s best leaders — love to see you and have join in.

Safe travels!
January 12, 2025 at 6:22 AM Everybody can reply
5 reposts 72 likes
1 5 72
nti.org
Nuclear Threat Initiative
@nti.org
Biopharma innovators and investors attending #JPM2025, RSVP now to join NTI | bio on Jan. 16 at 7:30 AM PT to explore how the shifting political environment & emerging biological risks could impact business opportunities & building global health security.
January 7, 2025 at 4:12 PM Everybody can reply
1 quotes 5 likes
1 5
drannecarpenter.bsky.social
Anne Carpenter
@drannecarpenter.bsky.social
Awesome first day of my first JPM!

Meeting investors for SyzOnc in person, loving getting to know random ppl working on random things and I think I had a smore for dinner last night?

I always lose my voice at networking events so we brought throat soothers as swag 😀 #JPM2025
mini-bag full of throat lozenges labeled "Cancer Sucks. Let's Save Lives Together. SyzOnc"
January 14, 2025 at 3:43 PM Everybody can reply
2 reposts 14 likes
2 14
rasushrestha.bsky.social
Dr Rasu Shrestha
@rasushrestha.bsky.social
Superb points below. Nothing is as simple as it could be in #healthcare.

#JPM2025 #JPM25 #biopharma #medsky
brianrifkin.bsky.social Brian Rifkin @brianrifkin.bsky.social · Jan 12
You know this isn’t how it works. The drug companies collude to keep prices high until and independent manufacturer steps in. Plus they modestly tweak molecules to keep patents. Big Pharma knows how to place the game to keep profits high.
rasushrestha.bsky.social Dr Rasu Shrestha @rasushrestha.bsky.social · Jan 12
💊 Drug companies stand to lose more than $400 billion in revenue as patents expire for Keytruda, Eliquis, Jardiance, Opdivo, and other blockbuster therapies. ~ @statnews.com

THIS will be a huge catalyst for deals at #JPM2025 this year!

#JPM25 #biopharma #medsky
January 12, 2025 at 11:07 PM Everybody can reply
2 reposts 12 likes
2 12
bonumtx.com
Bonum Therapeutics
@bonumtx.com
#FBF: Revisiting "In the Pink" at #JPM2025, a celebration of the contributions of women leaders in biotech & pharma—and their allies. Can you spot CBO Neela Patel & VP Cindy Yee in the #SeaOfPink?

Thanks to Biotech CEO Sisterhood, #Breaking7% & @cooleyllp.bsky.social for sponsoring! #ProjectMirror
A large group of women wearing items of pink clothing Two women, wearing pink and waving at the camera
January 31, 2025 at 8:19 PM Everybody can reply
1 reposts 1 likes
1 1
daphnezohar.bsky.social
Daphne Zohar
@daphnezohar.bsky.social
We are having #JPM2025 networking event on 1/14 at Persona. Meet our #BiotechHangout co-hosts and other colleagues with open bar thanks to our generous sponsors register here docs.google.com/forms/d/e/1F... #BioSky
https://bit.ly/41LDMIP
t.co
January 4, 2025 at 9:27 AM Everybody can reply
2 reposts 1 quotes 3 likes
2 3
rasushrestha.bsky.social
Dr Rasu Shrestha
@rasushrestha.bsky.social
This is going to be an eventful #JPM25 this year.

Spurred by #AI ’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund

www.statnews.com/2025/01/10/e... #medsky #JPM2025
Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.
www.statnews.com
January 11, 2025 at 8:13 PM Everybody can reply
2 likes
2
foresight-dx.bsky.social
Foresight Diagnostics
@foresight-dx.bsky.social
This morning, our CEO Jake Chabon presented at #JPM2025. It was great to connect with industry leaders and share our groundbreaking work on ultra-sensitive minimal residual disease (MRD) detection.

Learn more about Foresight and what's on the horizon for 2025: foresight-dx.com/press_releas...
January 15, 2025 at 9:57 PM Everybody can reply
thermalpr.com
Thermal
@thermalpr.com
🎤 Most notably, don't miss our client #CRISPR pioneer @jenniferdoudna.bsky.social's fireside chat sessions with @leileiwu.bsky.social at @endpts.com' #JPM2025 event (Tuesday 14 at 9am) and @natashaloder.bsky.social at Recursion and Economist Impact's "Era of TechBio" event (Wednesday 6:30pm).
January 13, 2025 at 1:51 AM Everybody can reply
1 reposts 1 quotes 2 likes
1 1 2
idolfisherman.bsky.social
Jang-Ho Cha
@idolfisherman.bsky.social
Attending #JPM2025. Union Square is overrun by nerds such as myself. Biotech has a gender problem. Attended four different receptions last night. M:F ratio is 10:1 no exaggeration. This should change. Thanks for coming to my TED talk.
January 14, 2025 at 4:22 PM Everybody can reply
1 reposts 4 likes
1 4
chimoose.com
Greg Matthews
@chimoose.com
I'm excited that HealthQuant is sponsoring this evening's Ticket to Biotech event at #JPM25 (Alongside @FleishmanHillard and AbbVie). Great group of biotech communications professionals. Come along and check it out! lu.ma/JPM2025 #Biotech #Pharma #PharmaSky
Invitation to the Ticket to Biotech networking reception at the JP Morgan Biotech Conference in San Francisco
January 13, 2025 at 5:53 PM Everybody can reply
1 quotes 4 likes
4
markfortner.bsky.social
Mark Fortner
@markfortner.bsky.social
#jpm2025
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
investor.lilly.com
January 13, 2025 at 11:09 PM Everybody can reply
endpts.com
Endpoints News
@endpts.com
Join us at #JPM2025 to hear from Maha Katabi, GP at Sofinnova Investments, in a discussion of the future of oncology R&D. What are the top priorities for 2025? How will research and investment dollars be allocated? Reserve your spot: events.endpts.com/jpm25/697639...
December 10, 2024 at 4:40 PM Everybody can reply
2 reposts
2